Expression of LINE-1 retrotransposons in human breast cancer.

Cancer

Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000.

Published: May 1994

Background: Several diseases have been linked to the insertion of human LINE-1 retrotransposons (L1Hs) into structural genes. Recently, the element has been shown to be expressed in a variety of adult and pediatric germ cell cancers, leading to speculation that L1Hs-induced insertion mutations may play a role in the etiology of some neoplasias.

Methods: An L1Hs-encoded protein (p40) was assayed in breast cancer cell lines by Western blotting and in solid tumors by immunohistochemical staining and Western blotting.

Results: L1Hs retrotransposons are expressed in a significant number of human breast cancers: expression was detected in 7 of 8 malignant cell lines and in 9 of 12 primary infiltrating ductal carcinomas. No expression was detected in two nonmalignant breast epithelial cell lines, five malignant B- or T-cell lines, tissue from a normal breast, a primary breast sarcoma, or a primary medullary carcinoma of the breast.

Conclusions: These results raise the possibility that L1Hs expression may contribute to the origin or progression of some breast cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19940501)73:9<2333::aid-cncr2820730915>3.0.co;2-4DOI Listing

Publication Analysis

Top Keywords

cell lines
12
line-1 retrotransposons
8
human breast
8
breast cancer
8
breast cancers
8
expression detected
8
breast
7
expression
4
expression line-1
4
retrotransposons human
4

Similar Publications

Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

View Article and Find Full Text PDF

Stemness-associated cell states are linked to chemotherapy resistance in AML. We uncovered a direct mechanistic link between expression of the stem cell transcription factor GATA2 and drug resistance. The GATA-binding protein 2 (GATA2) plays a central role in blood stem cell generation and maintenance.

View Article and Find Full Text PDF

Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.

Curr Treat Options Oncol

January 2025

Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, Zhejiang, China.

Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits.

View Article and Find Full Text PDF

Curcumin-coated iron oxide nanoparticles for photodynamic therapy of breast cancer.

Photochem Photobiol Sci

January 2025

Nanosensors Laboratory, Research & Development Institute, University of Vale do Paraíba, Av. Shishima Hifumi, 2911, Urbanova, São José dos Campos, São Paulo, Brazil.

Breast cancer is the deadliest cancer among women and its treatment using traditional methods leads the patient to experience adverse effects. However, photodynamic therapy (PDT) is a non-invasive therapy modality that works through a photosensitizing agent, which treating activated by a suitable light source, releases reactive oxygen species capable of treating cancer. Furthermore, recent research indicates that combining PDT and nanoparticles can enhance therapeutic effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!